Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis

被引:52
作者
Saleem, Sadaf [1 ]
Iqubal, Mohammad Kashif [1 ]
Garg, Sanjay [2 ]
Ali, Javed [1 ]
Baboota, Sanjula [1 ]
机构
[1] Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi 110062, India
[2] Univ South Australia UniSA, Sch Pharm & Med Sci, Adelaide, SA, Australia
关键词
T-lymphocytes; molecular targets; nano-carriers; polymeric nanoparticles; nanostructured lipid carriers; transferosomes; SOLID LIPID NANOPARTICLES; NF-KAPPA-B; TOPICAL DELIVERY; ANTIPSORIATIC ACTIVITY; SKIN PENETRATION; TRIAMCINOLONE ACETONIDE; DEFORMABLE LIPOSOMES; CYCLOSPORINE-A; CARRIERS; METHOTREXATE;
D O I
10.1080/17425247.2020.1758665
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Psoriasis is identified as an inflammatory, chronic, auto-immune disease requiring long-term treatment, imposing an unnecessary burden on the patient. A significant impediment for the treatment of dermatological disorders via transdermal route is the inability of drug molecules to cross the stratum corneum (SC), as the larger size of drug molecules inhibits them to pervade into the skin, thus hampering their absorption. Some drugs exhibit systemic side-effects, which curbs patient compliance, resulting in treatment discontinuation. Areas covered: This review aims to describe the detailed study such as demographic status, molecular factors of psoriasis, treatment with emerging combination therapy and role of nanotechnology tools in the treatment of psoriasis. Expert opinion: To overcome problems related to the conventional drug delivery system, several nanotechnology-based formulations have been devised to enhance bioavailability, drug permeation and accumulation in the skin. Nano-formulations provide better permeation, targeted delivery and enhanced efficacy, thus gaining enormous popularity for cutaneous disorders. This pervasive review provides an overview of the pathophysiology of the disease, its molecular targets and the available herbal, synthetic and combination treatment modalities. The review also systematizes recent works utilizing nano-carriers to improve the treatment denouement of psoriasis.
引用
收藏
页码:817 / 838
页数:22
相关论文
共 150 条
  • [1] Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study
    Abdelbary, Aly A.
    AbouGhaly, Mohamed H. H.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 485 (1-2) : 235 - 243
  • [2] Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study
    Abu Hashim, Irhan Ibrahim
    El-Magd, Noha Fawzy Abo
    El-Sheakh, Ahmed Ramadan
    Hamed, Mohammed Fawzy
    Abd El-Gawad, Abd El-Gawad Helmy
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 1059 - 1079
  • [3] Affandi AM, 2018, DERMATOL RES PRACT, V2018, P1
  • [4] Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis
    Agrawal, Yogeeta
    Petkar, Kailash C.
    Sawant, Krutika K.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 401 (1-2) : 93 - 102
  • [5] Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett-Burman design and characterization
    Ahmed, Tarek A.
    [J]. JOURNAL OF LIPOSOME RESEARCH, 2015, 25 (01) : 1 - 10
  • [6] Alam MS, 2016, IRAN J PHARM RES, V15, P35
  • [7] Resident skin cells in psoriasis:: a special took at the pathogenetic functions of keratinocytes
    Albanesi, Cristina
    De Pita, Ornella
    Girolomoni, Giampiero
    [J]. CLINICS IN DERMATOLOGY, 2007, 25 (06) : 581 - 588
  • [8] The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis
    Albanesi, Cristina
    Madonna, Stefania
    Gisondi, Paolo
    Girolomoni, Giampiero
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [9] [Anonymous], 2016, INDC submission by the Republic of Korea
  • [10] [Anonymous], 2012, CLIN IMMUNOLOGY PRIN